<DOC>
	<DOCNO>NCT00712894</DOCNO>
	<brief_summary>The purpose study evaluate efficacy three different vasodilator include diltiazem , verapamil nitroglycerin reversal no-reflow/slow-flow direct percutaneous coronary intervention acute myocardial infarction .</brief_summary>
	<brief_title>Effects Different Vasodilators Coronary No-reflow During primAry percuTaneous Coronary intErvention Patients With Acute Myocardial Infarction</brief_title>
	<detailed_description>No-reflow/slow-flow frequent observation direct PCI AMI associate poor clinical outcome . The present pharmacological management involve use different vasodilator include nitrate , verapamil , adenosine nicorandil . But randomized trial conduct assess agent , determine appropriate dosage . This prospective randomized study aim confirm favorable effect diltiazem no-reflow/slow-flow direct PCI AMI compare verapamil nitroglycerin .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Nitroglycerin</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<mesh_term>Diltiazem</mesh_term>
	<mesh_term>Vasodilator Agents</mesh_term>
	<criteria>Clinical diagnosis acute myocardial infarction Vessel TIMI flow &lt; grade Ⅲ postPCI Heart failure New York Heart Association ( NYHA ) class Ⅲ class Ⅳ Sick sinus syndrome Atrioventricular block ( grade Ⅱ ) SBP ≤ 90mmHg cardiogenic shock Heart Rate ≤60 bpm Pregnancy Renal hepatic failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Acute myocardial infarction</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>No-reflow phenomenon</keyword>
	<keyword>Vasodilator agent</keyword>
</DOC>